Get to know our clinical trials
Trial comparing the effect of abelacimab relative to dalteparin on venous thromboembolism (VTE) recurrence and bleeding in patients with VTE associated with gastrointestinal (GI) or genitourinary cancer.
THE AIM OF THE STUDY IS TO DETERMINE THE ABILITY OF ABELACIMAB TO REDUCE BLOOD CLOTTING WITH POSSIBLY FEWER BLEEDING EPISODES.
Technical Summary
- PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL, MASKED ENDPOINT STUDY COMPARING THE EFFECT OF ABELACIMAB RELATIVE TO DALTEPARIN ON VENOUS THROMBOEMBOLISM (VTE) RECURRENCE AND BLEEDING IN PATIENTS WITH VTE ASSOCIATED WITH GASTROINTESTINAL (GI) OR GENITOURINARY CANCERIMMUNOTHERAPY.
- Code EudraCT: 2021-003085-12
- Protocol number: ANT-008
- Promoter: Anthos Therapeutics
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.